North America Bladder Cancer Therapeutics and Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The North America Bladder Cancer Therapeutics and Diagnostics Market is Segmented by Product (Therapeutics and Diagnostics), Cancer Type, and Geography.

Market Snapshot

North Bladder Ca
Study Period: 2018 - 2026
Base Year: 2020
CAGR: 5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Certain factors that are driving the market growth include the increasing awareness about bladder diseases and available therapies, innovations in drug development, and increasing healthcare expenditure.

Based on the data from the International Agency for Research on Cancer 2018, bladder cancer is the sixth most commonly diagnosed cancer among males and the ninth leading cause of cancer deaths worldwide. Historically, bladder cancer has been associated with low patient awareness. However, in recent years, the awareness regarding bladder diseases and their management has drastically improved, particularly in developed nations. Also, the rise of immunotherapy therapies in cancer treatment has rekindled interest in eligible patients as it is a recently developed treatment modality, and has lower side-effects when compared to radiation therapy and chemotherapy, which are conventional therapeutic options in bladder cancer management. Therefore, the increasing awareness about bladder cancer and related therapies is fuelling the growth of the North American bladder cancer therapeutics and diagnostics market.

However, the accuracy of diagnostic tests like urine cytology for identifying bladder cancer is considerably low, particularly in asymptomatic patients with no history of bladder cancer. The symptoms for bladder cancer, like with most other cancers, manifest completely only in advanced stages, and early stages have no peculiar symptoms, which can assist in patient differentiation. High rate of failure in the early detection of bladder cancer is a direct outcome of this limitation. Therefore, the asymptomatic nature of bladder cancer is restricting the growth of the North American bladder cancer therapeutics and diagnostics market.

Scope of the Report

Bladder cancer arises from the epithelial lining of the urinary bladder. It is the ninth most common cancer worldwide, with the highest recurrence rate of any malignancy. There has been gradual development over the past ten years in bladder cancer, with a huge void of unmet needs.

By Product
By Therapeutics
By Diagnostics
Bladder Ultrasound
By Cancer Type
Transitional Cell Bladder Cancer
Squamous Cell Bladder Cancer
North America
United States

Report scope can be customized per your requirements. Click here.

Key Market Trends

Chemotherapy, by Therapeutics, is Expected to Hold a Significant Share Over the Forecast Period

Chemotherapeutics refers to the utilization of drugs to combat a certain disorder. Chemotherapy is the first choice for bladder cancer treatment. In bladder cancer, the drug is administered either intravesically or directly into the urinary bladder. The non-muscle invasive bladder cancer (NMIBC) treatment is generally performed by chemotherapy and BCG immunotherapy.

The most common drugs used, when administered along with radiation, are Cisplatin, Mitomycin, 5-Fluorouracil, also these in combination. Drugs used without radiation therapy are Methotrexate, Vinblastine, Doxorubicin, and Cisplatin. Some other drugs also used in bladder cancer are Gemcitabine, Paclitaxel, Carboplatin, Ifosfamide, Thiotepa, Pemetrexed, and Docetaxel. There has not been much development on bladder cancer chemotherapeutic agents, during the past decade. There exists a void in the market. The increasing aging population and the high incidence of bladder cancer among the population are expected to drive the market over the forecast period.

North America Bladder Cancer Therapeutics and Diagnostics Market 2.png

Competitive Landscape

The North American bladder cancer therapeutics and diagnostics market is highly competitive and consists of a number of major players. Companies, like AstraZeneca PLC, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Novartis AG, Pfizer Inc., Sanofi SA, and Johnson & Johnson (Janssen Pharmaceutical) hold the substantial market share in the North American bladder cancer therapeutics and diagnostics market.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Awareness on Bladder Diseases and Available Therapies

      2. 4.2.2 Increasing Healthcare Expenditure

      3. 4.2.3 Innovations in Drug Development

    3. 4.3 Market Restraints

      1. 4.3.1 Rise in the number of Patent Expirations

      2. 4.3.2 Asymptomatic Nature of the Disease

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Product

      1. 5.1.1 By Therapeutics

        1. Chemotherapy

        2. Immunotherapy

        3. Others

      2. 5.1.2 By Diagnostics

        1. Cystoscopy

        2. Bladder Ultrasound

        3. Urinalysis

        4. Others

    2. 5.2 By Cancer Type

      1. 5.2.1 Transitional Cell Bladder Cancer

      2. 5.2.2 Squamous Cell Bladder Cancer

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico


    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca PLC

      2. 6.1.2 Bristol-Myers Squibb Company

      3. 6.1.3 Eli Lilly and Company

      4. 6.1.4 F. Hoffmann-La Roche Ltd

      5. 6.1.5 GlaxoSmithKline PLC

      6. 6.1.6 Novartis International AG

      7. 6.1.7 Pfizer Inc.

      8. 6.1.8 Sanofi SA

      9. 6.1.9 Johnson & Johnson (Janssen Pharmaceutical)

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The North America Bladder Cancer Therapeutics and Diagnostics Market market is studied from 2018 - 2026.

The North America Bladder Cancer Therapeutics and Diagnostics Market is growing at a CAGR of 5% over the next 5 years.

Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Johnson & Johnson (Janssen Pharmaceutical), F. Hoffmann-La Roche Ltd are the major companies operating in North America Bladder Cancer Therapeutics and Diagnostics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!